Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer

European Journal of Cancer

Volumn 37, Issue 7, 2001, Pages 826-834

  Cunningham, D ^a   James, R D ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

5 Fluorouracil; Capecitabine; Colorectal cancer; Fluoropyrimidines; Irinotecan; Oral; Oxaliplatin; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 ETHYNYLURACIL; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ORZEL; OXALIPLATIN; OXONIC ACID; RALTITREXED; TEGAFUR; THYMIDYLATE SYNTHASE INHIBITOR;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035046218     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00052-1     Document Type: Review

References (59)

1. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
2. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
3. Patient preferences for oral versus intravenous palliative chemotherapy
4. A study of quality of life in cancer patients receiving palliative chemotherapy
5. Oral fluoropyrimidines in the treatment of colorectal cancer
6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
7. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
8. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer)
9. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
10. Current approaches to metastatic colorectal cancer
11. Clinical pharmacology of 5-fluorouracil
12. Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin
13. Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents
14. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
15. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study
16. 24h) with or without folinic acid (FA) vs bolus 5-Fu/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomised phase III study of the EORTC GITCCG and the AIO
17. Rationale for treatment design: Biochemical modulation of 5-fluorouracil by leucovorin
18. Final results of a randomised trial comparing Tomudex® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
19. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
20. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer
21. The value of quality of life (QL) outcomes in comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer
22. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
23. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
24. Tumour selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
25. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
26. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
27. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/Taxotere in human cancer xenografts
28. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models
29. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts
30. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
31. A phase III trial (SO14796) of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer
32. Comparison of oral capecitabine versus intravenous 5-fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
33. Capecitabine as first-line treatment for metastatic colorectal cancer (CRC): Integrated results of 1207 patients (pts) from 2 randomized, phase III studies
34. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
35. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer
36. Randomized comparative study of ORZEL® (oral uracil/tegafur (UFT)™) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU plus LV in patients with metastatic colorectal cancer
37. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer
38. Therapeutic selectivity of S-1, a new oral formulation of ftorafur (ft), 5-chloro-2,4-dihydroxypyridine (CDHP) and oxonic acid (oxo) in rats bearing advanced colorectal carcinoma
39. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
40. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma
41. Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer
42. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
43. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
44. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
45. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
46. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC)
47. Antitumour activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data
48. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
49. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
50. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)
51. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
52. High-dose oxaliplatin with the simplified 48h bimonthly leucovorin (LV) and 5-fluorouracil (5-FU) regimen in pretreated metastatic colorectal cancer (FOLFOX)
53. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
54. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
55. Phase I study of capecitabine in combination with a weekly schedule of irinotecan (CPT-11) as first-line chemotherapy in metastatic colorectal cancer
56. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: Results from a phase I study
57. Phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer
58. Phase II clinical trial with the combination of oxaliplatin-UFT-I, -leucovorin (OXA-UFT-I, LV) for the first-line treatment of advanced colorectal cancer (ACC). Preliminary results (Oncopaz Cooperative Group - Spain)
59. A randomized crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer